8-K: RxSight Slashes Full-Year 2025 Revenue Guidance Amidst Q2 Underperformance and Device Sales Decline

RxSight, Inc. announced preliminary second quarter 2025 financial results showing a revenue decrease and a significant downward revision of its full-year 2025 revenue guidance, driven by a sharp decline in Light Delivery Device sales.

Summary

• Preliminary second quarter 2025 revenue is expected to be approximately $33.6 million.
• Q2 2025 revenue represents a 4% decrease compared to the prior year period and an 11% decrease compared to the first quarter of 2025.
• The company sold 27,380 Light Adjustable Lenses (LAL/LAL+) in Q2 2025, a 1% decrease in procedure volume compared to Q1 2025, but a 13% increase compared to Q2 2024.
• The company sold 40 Light Delivery Devices (LDDs) in Q2 2025, a 45% decrease compared to Q1 2025 and a 49% decrease compared to Q2 2024.
• As of June 30, 2025, the installed base of LDDs stood at 1,084, representing a 34% expansion compared to 810 LDDs at the end of Q2 2024.
• Revised full-year 2025 revenue guidance is now in the range of $120.0 million to $130.0 million, a significant reduction from the previous guidance of $160.0 million to $175.0 million.
• The revised revenue guidance implies a decrease of 14% to 7% compared to 2024.
• Full-year 2025 gross margin guidance increased to a range of 72% to 74%, up from the previous range of 71% to 73%.
• Full-year 2025 operating expense guidance was reduced to a range of $145.0 million to $155.0 million, representing an implied increase of 7% to 14% compared to 2024.
• Operating expenses include non-cash stock-based compensation expense in the range of $27.0 million to $30.0 million.
• Preliminary cash, cash equivalents, and short-term investments as of June 30, 2025, are $227.5 million, a decrease of approximately $1.8 million from $229.3 million as of March 31, 2025.

Sentiment

Score: 3

Explanation: The significant downward revision of full-year revenue guidance and the preliminary Q2 revenue underperformance, particularly the sharp decline in LDD sales, indicate a negative overall sentiment. While gross margin guidance improved, the core revenue outlook is substantially weaker.

Positives

• Gross margin percentage guidance for full-year 2025 increased to a range of 72% to 74%.
• Light Adjustable Lens (LAL/LAL+) procedure volume increased 13% compared to the second quarter of 2024.
• The installed base of Light Delivery Devices (LDDs) expanded 34% year-over-year, reaching 1,084 units as of June 30, 2025.
• Operating expense guidance for full-year 2025 was reduced.

Negatives

• Preliminary Q2 2025 revenue of $33.6 million represents a 4% decrease compared to the prior year period and an 11% decrease compared to the first quarter of 2025.
• Full-year 2025 revenue guidance was significantly revised downward from $160.0 million $175.0 million to $120.0 million $130.0 million.
• Sales of Light Delivery Devices (LDDs) decreased significantly by 45% compared to Q1 2025 and 49% compared to Q2 2024.
• Management explicitly referred to the second quarter as experiencing 'underperformance'.

Risks

• Actual results may differ materially from forward-looking statements due to known and unknown risks, uncertainties, and other factors.
• Risks described in the Company's prior press releases and SEC filings, including Part I, Item 1A (Risk Factors) of the Annual Report on Form 10-K for the year-ended December 31, 2024, and any subsequent SEC filings.
• Preliminary financial and operational results are estimates and subject to completion of financial statements and review by the independent registered public accounting firm.
• Actual reported results could differ based on completion of quarter-end closing procedures, final adjustments, and developments that may arise prior to completion of quarterly financial statements.

Future Outlook

RxSight is evolving its commercial approach to re-direct more focus toward supporting customer success within new and existing practices. The company aims to deepen engagement with clinical partners to ensure they fully realize the benefits of adjustability and achieve superior patient outcomes, which is expected to drive further LAL adoption. For full-year 2025, the company has revised its revenue guidance downward to $120.0 million to $130.0 million, while increasing its gross margin percentage guidance to 72% to 74% and reducing operating expense guidance to $145.0 million to $155.0 million.

Management Comments

• "Guided by insights from our second quarter underperformance and building on our long-term vision, we are evolving our commercial approach to re-direct more of our focus toward supporting customer success within new and existing practices." Dr. Ron Kurtz, Chief Executive Officer and President of RxSight.
• "By deepening our engagement with our clinical partners, we believe we will be better positioned to ensure they can fully realize the benefits of adjustability and achieve the superior outcomes for their patients that ultimately drive further LAL adoption." Dr. Ron Kurtz, Chief Executive Officer and President of RxSight.

Industry Context

The ophthalmic medical device industry, particularly the segment focused on cataract surgery and intraocular lenses, is highly competitive and driven by technological innovation and clinical outcomes. RxSight's Light Adjustable Lens system offers a unique post-surgery adjustability feature, positioning it as a premium solution. The reported underperformance in LDD sales and overall revenue suggests potential challenges in market penetration or adoption rates, despite the growth in LAL procedure volume and installed LDD base. This could indicate a shift in sales strategy or market saturation for new device placements, requiring a greater focus on recurring revenue from lens sales and customer retention.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess RxSight's performance against global benchmarks. Therefore, a direct comparison to industry standards with specific examples is not possible based solely on the provided text.

Stakeholder Impact

• Shareholders: Likely to experience a negative impact on share price due to the significant downward revision of revenue guidance and preliminary Q2 underperformance.
• Customers (Clinical Partners): The company's evolving commercial approach to focus more on supporting customer success and deepening engagement could be beneficial for existing and new practices.
• Employees: Potential impact on sales teams and overall strategy due to the shift in commercial focus and revised financial outlook.

Next Steps

• Host a conference call on Tuesday, July 8, 2025, at 5:00 p.m. Eastern Time to discuss preliminary Q2 2025 revenue results and revised full-year guidance.
• Report unaudited financial results for the second quarter of 2025 after market close on Thursday, August 7, 2025.
• Management will discuss comprehensive Q2 results during a conference call shortly following the August 7th announcement.
• Evolve commercial approach to re-direct focus toward supporting customer success within new and existing practices.
• Deepen engagement with clinical partners to drive further LAL adoption.

Key Dates

Recommendation

Keywords

RxSight, RXST, ophthalmic medical device, cataract surgery, Light Adjustable Lens, LAL, Light Delivery Device, LDD, financial results, revenue guidance, preliminary results, Q2 2025, 2025 guidance, medical technology, vision correction